Iressa for NSCLC - horizon scanning review

Record ID 32002000538
Authors' objectives:

To summarise the current research evidence on Iressa for non small cell lung cancer (NSCLC).

Authors' recommendations: - Clinical impact: It is difficult to anticipate the place of Iressa in the management of non-small cell lung cancer given the information that is currently available but any additional short or long-term increase in survival may be significant in this patient group. - Service impact: The introduction of Iressa for non-small cell lung cancer is unlikely to have a significant impact on service provision, but patient selection will be important. - Financial and overall NHS impact: It is difficult to estimate the potential financial impact associated with the introduction of Iressa for non-small cell lung cancer at this time but if used as an add-on therapy will represent an additional drug cost. Iressa may need to be continued for the remaining life of the patient rather than used as a course of treatment.
Authors' methods: Overview
Project Status: Completed
Year Published: 2002
URL for published report:
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Antineoplastic Agents
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Quinazolines
Organisation Name: NIHR Horizon Scanning Centre
Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
Contact Email:
Copyright: National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.